{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:46Z","timestamp":1792012906319,"version":"4.4.0"},"reference-count":96,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Juvenile idiopathic arthritis (JIA) is a heterogeneous group of diseases with probably differential underlying physiopathology. Despite the revolutionary era of biologics, some patients remain difficult to treat because of disease severity, drug adverse events, drug allergy or association with severe comorbidities, i.e., uveitis, interstitial lung disease and macrophagic activation syndrome. Janus Kinase (JAK) inhibitors are small molecules that target JAK\/Signal Transducers and Activators of Transcription (STAT) pathways, which could then prevent the activity of several proinflammatory cytokines. They may provide a useful alternative in these cases of JIA or in patients actually affected by Mendelian disorders mimicking JIA, such as type I interferonopathies with joint involvement, and might be the bridge for haematopoietic stem cell transplantation in these disabling conditions. As these treatments may have side effects that should not be ignored, ongoing and further controlled studies are still needed to provide data underlying long-term safety considerations in children and delineate subsets of JIA patients that will benefit from these promising treatments.<\/jats:p>","DOI":"10.3390\/jcm12144695","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:56:47Z","timestamp":1689555407000},"page":"4695","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-333X","authenticated-orcid":false,"given":"Isabelle","family":"Melki","sequence":"first","affiliation":[{"name":"General Paediatrics, Department of Infectious Disease and Internal Medicine, Robert Debr\u00e9 University Hospital, APHP, Nord\u2014Universit\u00e9 Paris Cit\u00e9, F-75020 Paris, France"},{"name":"Paediatrics, Rheumatology and Paediatric Internal Medicine, Children\u2019s Hospital, F-33000 Bordeaux, France"},{"name":"Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Universit\u00e9 Paris Cit\u00e9, Inserm UMR 1163, F-75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2798-9141","authenticated-orcid":false,"given":"Marie-Louise","family":"Fr\u00e9mond","sequence":"additional","affiliation":[{"name":"Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Universit\u00e9 Paris Cit\u00e9, Inserm UMR 1163, F-75015 Paris, France"},{"name":"Paediatric Haematology-Immunology and Rheumatology Unit, Necker Hospital, APHP, Centre\u2014Universit\u00e9 Paris Cit\u00e9, F-75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/keab673","article-title":"Interfering with interferons: Targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)","volume":"61","author":"Verweyen","year":"2022","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1084\/jem.20070070","article-title":"Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade","volume":"204","author":"Allantaz","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1084\/jem.20170412","article-title":"A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis","volume":"214","author":"Cepika","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/BOR.0000000000000526","article-title":"Systemic juvenile idiopathic arthritis and macrophage activation syndrome: Update on pathogenesis and treatment","volume":"30","author":"Yasin","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14712598.2020.1733524","article-title":"Current and emerging biologics for the treatment of juvenile idiopathic arthritis","volume":"20","author":"Cimaz","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2021.08.004","article-title":"JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition","volume":"148","author":"Luo","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11926-018-0792-7","article-title":"JAK inhibitors in rheumatology: Implications for paediatric syndromes?","volume":"20","author":"Kerrigan","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: From basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaci.2021.07.028","article-title":"JAK inhibition in the type I interferonopathies","volume":"148","author":"Crow","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"Holland","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/rheumatology\/keaa576","article-title":"Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: Results from a long-term study","volume":"60","author":"Smolen","year":"2021","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3389\/fimmu.2018.01510","article-title":"Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system","volume":"9","author":"Kubo","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2021.1902617","article-title":"Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Enejosa","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"Song","year":"2019","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Pangan","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: Proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"ref_31","first-page":"293","article-title":"Sequential tocilizumab and tofacitinib treatment for systemic juvenile idiopathic arthritis: A case report","volume":"10","author":"Zhang","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2022","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Pin, A., Tesser, A., Pastore, S., Moressa, V., Valencic, E., Arbo, A., Maestro, A., Tommasini, A., and Taddio, A. (2020). Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207767"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/1756-185X.14324","article-title":"Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: A study from Bangladesh","volume":"25","author":"Rahman","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Vuki\u0107, V., Smajo, A., Vidovi\u0107, M., Vukojevi\u0107, R., Harja\u010dek, M., and Lamot, L. (2021). Beyond the guidelines management of juvenile idiopathic arthritis: A case report of a girl with polyarticular disease refractory to multiple treatment options and Leri Weill syndrome. BMC Pediatr., 21.","DOI":"10.1186\/s12887-021-02494-6"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e20182845","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","volume":"143","author":"Huang","year":"2019","journal-title":"Pediatrics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/RHU.0000000000000456","article-title":"Tofacitinib response in juvenile idiopathic arthritis (JIA) and collagenous colitis","volume":"22","author":"Tseng","year":"2016","journal-title":"J. Clin. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"820586","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: Single centre experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/ard-2022-223815","article-title":"Baricitinib for juvenile idiopathic arthritis: A monocentric case series","volume":"82","author":"Maccora","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1136\/annrheumdis-2020-216983","article-title":"Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: A case report","volume":"81","author":"Hadchouel","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e002611","DOI":"10.1136\/rmdopen-2022-002611","article-title":"Complications of complications: Diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis","volume":"9","author":"Macaraeg","year":"2023","journal-title":"RMD Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: A double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/art.22381","article-title":"Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-term followup study","volume":"56","author":"Saurenmann","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_44","first-page":"1107","article-title":"Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: The SHARE initiative","volume":"77","author":"Constantin","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_48","first-page":"1","article-title":"Beneficial Effect of Upadacitinib in an Adult Patient with Juvenile Idiopathic Arthritis-associated Uveitis after Unsatisfactory Response to Tofacitinib: A Case Report","volume":"31","author":"Heinz","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","article-title":"Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: Study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)","volume":"22","author":"Ramanan","year":"2021","journal-title":"Trials"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","article-title":"Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles","volume":"81","author":"Saper","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1136\/annrheumdis-2020-217000","article-title":"Response to: \u201cEffectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: Case report\u201d by Bader-Meunier et al","volume":"81","author":"Saper","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10875-022-01353-y","article-title":"Improvement of Refractory Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease with Single-Agent Blockade of IL-1\u03b2 and IL-18","volume":"43","author":"Rood","year":"2023","journal-title":"J. Clin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of type I interferon signaling in pediatric inflammatory disease","volume":"37","author":"Rice","year":"2017","journal-title":"J. Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1164\/rccm.201903-0659OC","article-title":"Synergistic Signaling of TLR and IFN\u03b1\/\u03b2 Facilitates Escape of IL-18 Expression from Endotoxin Tolerance","volume":"201","author":"Verweyen","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"23247096221077836","DOI":"10.1177\/23247096221077836","article-title":"Severe immediate and delayed hypersensitivity reactions to biologics in a toddler with systemic juvenile idiopathic arthritis","volume":"10","author":"Bilcha","year":"2022","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: Past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1126\/science.abc3545","article-title":"Type III interferons disrupt the lung epithelial barrier upon viral recognition","volume":"369","author":"Broggi","year":"2020","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I interferonopathies: A novel set of inborn errors of immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11926-020-00909-4","article-title":"Type I Interferonopathies: From a Novel Concept to Targeted Therapeutics","volume":"22","author":"Melki","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12969-020-00425-w","article-title":"Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: Report of a new phenotype","volume":"18","author":"Clarke","year":"2020","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jaip.2020.11.007","article-title":"Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients","volume":"9","author":"Hadchouel","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10875-021-00974-z","article-title":"STING-Mediated Lung Inflammation and Beyond","volume":"41","author":"Crow","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"ref_66","first-page":"e171","article-title":"Rheumatoid factor positive polyarticular juvenile idiopathic arthritis associated with a novel COPA mutation","volume":"60","author":"Bustaffa","year":"2020","journal-title":"Rheumatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ajhg.2014.12.014","article-title":"A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome","volume":"96","author":"Rutsch","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.40179","article-title":"Musculoskeletal Disease in MDA5-Related Type I Interferonopathy: A Mendelian Mimic of Jaccoud\u2019s Arthropathy","volume":"69","author":"Ngoumou","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.5152\/eurjrheum.2019.18177","article-title":"Baricitinib in therapy of COPA syndrome in a 15-year-old girl","volume":"7","author":"Krutzke","year":"2019","journal-title":"Eur. J. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12969-022-00686-7","article-title":"Precision treatment of Singleton Merten syndrome with ruxolitinib: A case report","volume":"20","author":"Broser","year":"2022","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/art.38877","article-title":"Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis","volume":"67","author":"Wakil","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpam.2020.11.005","article-title":"New or vanishing frontiers: LACC1-associated juvenile arthritis","volume":"8","author":"Yateem","year":"2021","journal-title":"Int. J. Pediatr. Adolesc. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e20201006","DOI":"10.1084\/jem.20201006","article-title":"LACC1 deficiency links juvenile arthritis with autophagy and metabolism in macrophages","volume":"218","author":"Omarjee","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: Results from the open-label, randomised controlled ORAL Surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: Final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s13365-017-0558-4","article-title":"Fatal ruxolitinib-related JC virus meningitis","volume":"23","author":"Ballesta","year":"2017","journal-title":"J. Neurovirol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: Systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous Thromboembolism Risk with JAK Inhibitors: A Meta-Analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis","volume":"71","author":"DeMasi","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_84","first-page":"1062","article-title":"Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2\/STAT3","volume":"135","author":"Krichevsky","year":"2020","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00296-019-04303-x","article-title":"Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib","volume":"39","author":"Novikova","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jdcr.2019.03.024","article-title":"Palmoplantar pustulosis-like eruption following tofacitinib therapy for juvenile idiopathic arthritis","volume":"5","author":"Shibata","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-020-00938-z","article-title":"Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment","volume":"43","author":"Veeravalli","year":"2020","journal-title":"Drug Saf."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/17425255.2021.1862084","article-title":"Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity","volume":"17","author":"Alim","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"717388","DOI":"10.3389\/fimmu.2021.717388","article-title":"Emerging place of JAK inhibitors in the treatment of inborn errors of immunity","volume":"12","author":"Hadjadj","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"eaat3834","DOI":"10.1126\/sciadv.aat3834","article-title":"Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis","volume":"4","author":"Tvorogov","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-020-02199-8","article-title":"Temporary interruption of baricitinib: Characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis","volume":"22","author":"Emery","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"eaay4447","DOI":"10.1126\/scitranslmed.aay4447","article-title":"JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function","volume":"12","author":"Adam","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Quartier, P. (2022). Systemic juvenile idiopathic arthritis\/pediatric still\u2019s disease, a syndrome but several clinical forms: Recent therapeutic approaches. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051357"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13075-022-02913-8","article-title":"Single-cell analysis reveals heterogeneity of juvenile idiopathic arthritis fibroblast-like synoviocytes with implications for disease subtype","volume":"24","author":"Simonds","year":"2022","journal-title":"Arthritis Res. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/14\/4695\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:12:23Z","timestamp":1760127143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/14\/4695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":96,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jcm12144695"],"URL":"https:\/\/doi.org\/10.3390\/jcm12144695","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}